ATAI Investor Day Presentation Deck
RL-007 significant clinical learning & memory effects
Phase 1-reverses cholinergic memory
challenge better than market leader Aricept
(donepezil)
D
.01
.05
.10
2 hr Placebo/Scopolamine vs Baseline
Theta (UV) Alpha 1 (UV) Alpha 2 (UV) Beta (UV)
.10
.06
.01
Delta (UV)
Inhibited scopolamine induced EEG
changes in Alpha and Theta
atai
LIFE SCIENCES
Placebo
(Cohen's d effect size)
Diff. vs.
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
Pregabalin
(50-100 mg TID)
Time point
RL-007
I
RL-007
(40 or 80 mg TID) (150 or 300 mg TID)
+1h
+2b
+4h
30 mg/Scop vs. Placebo/Scop
[
RL-007 low doses enhanced learning and memory
Verbal Learning (DPNP)
Delayed Recall (DPNP)
Delta (V)
(Cohen's d effect size)
Diff. vs. Placebo
0.4
0.3
0.1
-0.1
-0.2
II
-0.3
TE
Theta (V)
]}
II
Alpha 1 (V)
11
Dose
(Phase 2 exploratory endpoints - 180 patients)
Alpha 2 (V)
Beta (V)
**
RL-007
Pregabalin
RL-007
(50-100 mg TID) (40 or 80 mg 1D) (150 or 300 mg TID)
Dose
Indicates direction of improvement
* = P<0.05 vs Placebo; **missed significance (P=0.075); Diabetic Peripheral Neuropathic Pain (DPNP) n=60 patients/treatment group; dosed TID; randomized, cross-over design
RL-007 significantly reverses memory deficits at lowest dose and delays recovery at extremely high dose
Continuity of Attention
Delayed Word Recall
0
-2
12
44
Pre-dose
15h
0
-S
-15
-201
-25
Pre-dose
1.5h
3h
4.5h
Placebo
Phase 2 - exploratory endpoint analysis
shows statistically significant & clinically
meaningful positive learning & memory
effects
■ 30mg RL-007
► 150mg RL-007
◄ 750mg RL-007
"The effects on delayed word recall were more marked than seen with the target clinical dose of
Aricept (donepezil), the most widely prescribed anti-Alzheimer's drug" 1
*CSR 209323-502: P<0.05, n = 18; CNS effects also monitored by EEG
1: Keith Wesnes in CDR study report
131View entire presentation